All Projects

OxyPrem

Brain oxygen measurement for preterm infants

Potential

While modern medicine has enabled more premature infants to survive, the ultimate goal is more healthy survivors. Achieving this goal would greatly improve quality of life and drastically reduce healthcare costs by avoiding lifelong consequences. OxyPrem, a specialized, high-tech medical device, has the potential to play a significant role in making this a reality.

News

30-06-2024

Oxygenating Innovation

Our alumni project, OxyPrem (now OxyPrem AG), was recently featured in Ticino Management, a Lugano-based publication.

29-03-2022

OxyPrem receives SERI-funded EIC Accelerator Grant

As Switzerland is currently not associated with Horizon Europe, the start-ups will receive a ‘SERI-funded EIC Accelerator Grant’ from the federal government.

Key Figures

2018-22

Wyss Zurich period

12

Team size

Project Description

Preterm birth and its direct consequences are the leading cause of death for children under five years of age worldwide. Fifteen million infants are born prematurely every year, and about one million deaths are associated with prematurity. Societies around the globe are addressing this problem.

OxyPrem 1.4 is a next-generation medical device that monitors brain oxygen levels of preterm infants in real time, using harmless, non-invasive near-infrared light. It continuously measures local oxygenation with the precision and accuracy that are needed to assist in clinical decision-making for these high-risk patients.

OxyPrem is reusable and sturdy, offering a feasible solution even for challenging environments. The team is working towards making the device fully compatible with standard hospital monitors. At Wyss Zurich, OxyPrem was introduced to clinical care on a wider scale; 30 hospitals in six European countries have been using OxyPrem to date as part of a large-scale multicenter clinical study that is accelerating the medical community’s efforts to make brain oxygen measurement a standard component of clinical care.